August 3, 2022
Life Sciences
  • CivicaScript, the subsidiary of the hospital-owned nonprofit Civica Rx, will release its first drug manufactured and sold by the company. The drug is a generic version of the prostate cancer prescription drug abiraterone and will likely cost patients thousands of dollars less a month. CivicaScript chose abiraterone because of the high list price and significant patient need. The company hopes that their transparent approach “will translate into there being less opaqueness and fewer people being hurt by pricing on generic.” (Article here)